[Fundamental and clinical studies of ceftazidime in the pediatric field]. 1984

T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga

Ceftazidime ( CAZ ), a newly-developed parenteral cephem antibiotic, was administered to 8 children; by one shot intravenous (i.v.) injection in the doses of 20 and 40 mg/kg each to 2 children, and by 30 minutes' i.v. drip infusion in the doses of 10 and 20 mg/kg each to 2 children, and the serum levels, urinary levels and recovery rates were determined. CAZ was also administered to 2 patients with purulent meningitis, one complicated with subdural abscess and the other with bacteremia, in the doses of 19.2 and 50.7 mg/kg, respectively, by one shot i.v. injection, and the CSF level of CAZ was determined. In addition, CAZ was administered to 2 children with acute bronchitis, 1 with chronic bronchitis, 37 with pneumonia, 3 with pleuropneumonia, 1 each for purulent meningitis, purulent meningitis accompanied with subdural abscess and purulent meningitis with bacteremia, 5 with urinary tract infections and 3 with purulent lymphadenitis (total 54 children), in the mean dose of 85.8 mg/kg/day mostly in 4 divided doses by one shot i.v. injection for 9 days on the average, and clinical effectiveness and bacteriological response were evaluated in these cases, and adverse events and abnormal laboratory findings were examined in the 66 cases which included 12 drop-out cases. 1. After the administration of CAZ to 4 children; 20 and 40 mg/kg each to 2 children, by one shot i.v. injection, the mean serum levels got to the peak of 115.8 and 199.5 mcg/ml, respectively, at 5 minutes. The results were good, showing dose response. The mean half-lives were 1.48 and 1.37 hours, respectively. After the administration of 10 and 20 mg/kg of CAZ each to 2 children by 30 minutes' i.v. drip infusion, the mean serum levels got to the peak of 58.5 and 80.0 mcg/ml, respectively, on completion of the administration, showing dose response. The mean half-lives were 1.06 hours in the former 2 cases, and 1.38 and 3.26 hours, respectively, in the latter 2 cases. The reason for the prolongation observed in 1 case was not clear. 2. In the above mentioned each 2 cases receiving one i.v. injection, the mean urinary levels got to the peak of 4,240 and 4,445 mcg/ml, respectively, at 0-2 hours after the administration , and the urinary recovery rates during the first 6 hours were high, 95.7% and 99.5%, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
August 1986, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
March 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
March 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
March 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
March 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
March 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
March 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
January 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
March 1984, The Japanese journal of antibiotics,
T Motohiro, and K Tanaka, and T Koga, and Y Shimada, and N Tomita, and Y Sakata, and T Fujimoto, and T Nishiyama, and K Ishimoto, and K Tominaga
January 1984, The Japanese journal of antibiotics,
Copied contents to your clipboard!